The US Department of Agriculture approved the genetically modified purple tomato to extend its shelf life and boost nutritional quality almost 15 years after its development.
According to biochemist Cathie Martin, she and her colleagues at Norfolk Plant Scientists (NPS) have been experimenting with pigment production in flowering plants for over two decades, and they've spent almost 15 months developing the purple tomato.
The NPS has been focusing on anthocyanins, the antioxidant-rich pigments that give blackberries and blueberries their signature shades.
Domesticated tomatoes already have genes to produce anthocyanins, but they are not 'turned on.' By carefully adding two genes, the tomatoes and juice become a rich source of antioxidants, because purple pigments are made in the whole tomato, not just the skins.
While there are already some purple-skinned tomatoes, their pigments mostly stop at the outer layers and don't accumulate in the fruit itself.
The NPS also emphasized that there is increasing evidence to show that antioxidants work much better when consumed within foods.
The USDA Animal and Plant Health Inspection Service (APHIS) reported that the tomato was modified to alter its color and enhance its nutritional quality, adding that the plant is unlikely to pose an increased plant pest risk compared to other cultivated tomatoes.
Nathan Pumplin, the CEO of NPS' US-based commercial business, said they are optimistic that they can begin limited distribution of purple tomatoes in the US by 2023.


US Stock Futures Flat as Fed Minutes, Earnings Loom
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
New York Declares Measles Disaster Emergency as Cases Surge
Trump Opens Tax-Exempt Dyed Diesel Access as Fuel Prices Surge
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook
Kalshi Withdraws PEPE Perpetual Futures Filing
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
Dollar Retreats From 18-Month High as Euro Rebounds
Bitmine to Stop Ethereum Buying After Reaching 5% ETH Supply
Gold Prices Rise as Dollar Weakens, Treasury Yields Ease
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal
Trump Signs Order to Cut Routine Childhood Vaccines 



